BOS-580-202: A Phase 2, randomized, double-blinded, placebo-controlled study of efimosfermin alfa in participants with biopsy-confirmed cirrhosis (compensated) due to metabolic dysfunction-associated steatohepatitis (MASH)
Clinical Trial Grant
Administered By
Radiology, Abdominal Imaging
Awarded By
M3 Wake Research Inc
Start Date
May 7, 2025
End Date
January 31, 2027
Administered By
Radiology, Abdominal Imaging
Awarded By
M3 Wake Research Inc
Start Date
May 7, 2025
End Date
January 31, 2027